81 related articles for article (PubMed ID: 7168802)
1. Changes in the rosette forming capacity of lymphocytes after surgery or surgery and immunochemotherapy of malignant melanoma in man.
Hadjikirova M; Boeva M; Ikonopisov R
Biomed Pharmacother; 1982; 36(5):257-9. PubMed ID: 7168802
[TBL] [Abstract][Full Text] [Related]
2. [Results in the use of immunochemotherapy in patients with cutaneous malignant melanoma].
Calbo L; Gorgone S; Palmeri R; Salibra M; Melita P
Chir Ital; 1983 Aug; 35(4):519-25. PubMed ID: 6680859
[TBL] [Abstract][Full Text] [Related]
3. [Results of immunochemotherapy in malignant melanoma].
Duchková H; Richter J; Kubíková M; Peska J; Ragan J; Vohryzková E; Hrivnáková J; Kvasnicka J
Cesk Dermatol; 1980 Aug; 55(4):277-80. PubMed ID: 7407970
[No Abstract] [Full Text] [Related]
4. Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly study of melanoma patients II. Changes in serum immunoglobulins and lymphoid cell subpopulations.
Thatcher N; Swindell R; Crowther D
Clin Exp Immunol; 1979 Jun; 36(3):456-64. PubMed ID: 487647
[TBL] [Abstract][Full Text] [Related]
5. [T-lymphocytes in the peripheral blood. Study on 113 patients with malignant melanoma].
Klein R; Krüger GR; Sesterhenn K
Z Hautkr; 1978 Feb; 53(3):62-6. PubMed ID: 305173
[TBL] [Abstract][Full Text] [Related]
6. Influence of therapy on the antioxidant status in patients with melanoma.
Gadjeva V; Dimov A; Georgieva N
J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
[TBL] [Abstract][Full Text] [Related]
7. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
Agarwala SS; Neuberg D; Park Y; Kirkwood JM
Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
[TBL] [Abstract][Full Text] [Related]
8. [Multiple BCG-induced ulcers after subcutaneous vaccination in the framework of immunochemotherapy in malignant melanoma].
Korting HC; Strasser S; Konz B
Hautarzt; 1988 Mar; 39(3):170-3. PubMed ID: 3378889
[TBL] [Abstract][Full Text] [Related]
9. [Adjuvant chemotherapy in malignant melanoma after pretherapeutic sensitivity testing].
Zaumseil RP; Wohlrab W; Fiedler H; Wozniak KD
Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(5):721-4. PubMed ID: 6172340
[No Abstract] [Full Text] [Related]
10. [Experience with adjuvant chemoimmunotherapy with DTIC and BCG in malignant melanoma (author's transl)].
Pullmann H; Muth M
Z Hautkr; 1982 Feb; 57(4):294-7. PubMed ID: 7080583
[No Abstract] [Full Text] [Related]
11. Reactivity of peripheral blood lymphocytes in hamsters with transplanted melanomas in the rosette test.
Kozłowska K; Zurawska-Czupa B
Arch Immunol Ther Exp (Warsz); 1984; 32(1):67-70. PubMed ID: 6332595
[TBL] [Abstract][Full Text] [Related]
12. Current concepts in the management of malignant melanoma.
Lichtenfeld JL
Am J Med Sci; 1976; 272(2):185-95. PubMed ID: 1008080
[No Abstract] [Full Text] [Related]
13. Micronucleus analysis in peripheral blood lymphocytes from melanoma patients treated with dacarbazine.
Miele M; Bonassi S; Bonatti S; Martini E; Miglio L; Ottaggio L; Queirolo P; Sertoli M; Abbondandolo A
Anticancer Res; 1998; 18(3B):1967-71. PubMed ID: 9677451
[TBL] [Abstract][Full Text] [Related]
14. Letter: Chemoimmunotherapy of malignant melanoma.
N Engl J Med; 1975 Jan; 292(3):159-60. PubMed ID: 1196343
[No Abstract] [Full Text] [Related]
15. Thymostimulin therapy in melanoma patients: correlation of immunologic effects with clinical course.
Bernengo MG; Fra P; Lisa F; Meregalli M; Zina G
Clin Immunol Immunopathol; 1983 Sep; 28(3):311-24. PubMed ID: 6603936
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.
Konjević G; Jović V; Radulović S; Jelić S; Dzodić R; Spuzić I
Neoplasma; 2001; 48(3):175-81. PubMed ID: 11583285
[TBL] [Abstract][Full Text] [Related]
17. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
[TBL] [Abstract][Full Text] [Related]
18. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
Kretschmer L; Helmbold P; Emmert S; Marsch WC
Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
[TBL] [Abstract][Full Text] [Related]
19. [Functional E rosette study pre and post laser treatment in malignant ocular melanoma].
Tarnavschi R; Cârstocea B; Ciotaru D; Ursaciuc C; Antihi M; Stroilă C
Oftalmologia; 1992; 36(2):119-25. PubMed ID: 1525139
[TBL] [Abstract][Full Text] [Related]
20. [Comparative examinations of the effect of general and local anesthesia upon the T-lymphocytes in melanoma operations (author's transl)].
Seebacher C; Bässler E
Arch Geschwulstforsch; 1981; 51(2):179-86. PubMed ID: 6973960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
